Baseline MRI-based radiomics model assisted predicting disease progression in nasopharyngeal carcinoma patients with complete response after treatment

Table 1 Baseline clinical characteristics of the patients in the disease progression group and non-recurrence/non-disease progression group

Clinical characteristic	Disease progression group (n = 76)	Non-disease progression group (n = 95)	P value
Age (mean ± SD, years)	46.0 ± 12.4	42.0 ± 12.7	0.04*
Gender			0.01*
Male	66	67
Female	10	28
Histology			0.07
Differentiated Non-keratinising	45	43
Undifferentiated Non-keratinising	31	52
T stage			0.79
T1	8	15
T2	14	17
T3	31	35
T4	23	28
N stage			0.22
N0	3	9
N1	21	34
N2	36	39
N3	16	13
Overall stage			0.52
I	0	1
II	8	11
III	28	41
IV	40	42
Treatment			0.50
A	12	10
B	39	45
C	3	7
D	22	33
EA-IgA
positive	23	30	0.85
negative	53	65
VCA-IgA
positive	53	57	0.19
negative	23	38
Smoking			0.02*
Yes	44	38
No	32	57

Treatment: A-Radiotherapy only, B-Chemotherapy + Radiotherapy, C-Targeted therapy + Radiotherapy, D-Concurrent Chemoradiotherapy + Targeted Therapy, E-Chemotherapy + Targeted Therapy; * indicates statistical significant difference

ISSN: 1470-7330